Ceftolozane and Tazobactam

Aka: Ceftolozane and Tazobactam, Zerbaxa

advertisement

II. Indications

  1. Coverage
    1. Gram-Negative Bacteria (aerobes and Anaerobes)
    2. Multidrug Resistant Enterobacteriaceae (Ceftazidime-resistant, ESBL)
    3. Bacteroides
    4. Prevotella
    5. Pseudomonas aeruginosa
  2. Conditions
    1. Complicated intra-abdominal infections (with Metronidazole)
    2. Complicated Urinary Tract Infections including Pyelonephritis
    3. Hospital Acquired Pneumonia (and Ventilator-Associated Pneumonia)

III. Contraindications

  1. Not FDA approved for use in children

IV. Dosing

  1. Standard Dose (intra-abdominal infections, Complicated UTI)
    1. Infuse 1.5 g IV every 8 hours
  2. High Dose (Hospital Acquired Pneumonia, Ventilator-Associated Pneumonia)
    1. Infuse 3 g IV over 1 hour every 8 hours
  3. Renal Dosing
    1. eGFR 30 to 50 ml/min: 750 mg IV every 8 hours
    2. eGFR 15 to 29 ml/min: 375 mg IV every 8 hours
    3. eGFR <15 ml/min or Hemodialysis: 750 mg IV Load, then 150 mg IV every 8 hours after Hemodialysis

V. Safety

  1. Pregnancy Category B
  2. Unknown Safety in Lactation

VI. Resources

  1. Ceftolozane and Tazobactam (Zerbaxa)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f

VII. References

  1. Sorbera (2014) P T 39(12):825-32 +PMID: 25516692 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Ceftolozane and Tazobactam." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Related Topics in Pharmacology

advertisement